Cerus Co. (NASDAQ:CERS) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC boosted its holdings in shares of Cerus Co. (NASDAQ:CERS) by 202.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 57,765 shares of the biotechnology company’s stock after purchasing an additional 38,663 shares during the period. EntryPoint Capital LLC’s holdings in Cerus were worth $109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wasatch Advisors LP grew its stake in Cerus by 11.2% during the 4th quarter. Wasatch Advisors LP now owns 6,530,019 shares of the biotechnology company’s stock valued at $14,105,000 after acquiring an additional 656,971 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Cerus by 105.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,107,740 shares of the biotechnology company’s stock valued at $2,094,000 after purchasing an additional 568,107 shares during the last quarter. Easterly Investment Partners LLC acquired a new position in Cerus in the 1st quarter valued at about $405,000. Nikko Asset Management Americas Inc. boosted its holdings in Cerus by 2.4% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 7,750,700 shares of the biotechnology company’s stock valued at $14,571,000 after purchasing an additional 182,629 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Cerus by 2.4% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock valued at $14,649,000 after purchasing an additional 182,629 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Price Performance

Shares of Cerus stock opened at $2.38 on Friday. The business has a 50-day moving average of $1.91 and a 200 day moving average of $1.93. Cerus Co. has a 12 month low of $1.21 and a 12 month high of $3.08. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.72 and a current ratio of 2.41.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $38.37 million during the quarter, compared to analysts’ expectations of $36.40 million. Cerus had a negative net margin of 19.27% and a negative return on equity of 58.65%. Equities analysts anticipate that Cerus Co. will post -0.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on CERS. Craig Hallum started coverage on shares of Cerus in a report on Friday, April 12th. They issued a “buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald raised their price target on Cerus from $3.00 to $4.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.